Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer

Sawada, M.; Inagaki, M.; Hirota, Y.; Hongo, J.; Ozaki, M.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(11): 3091-3094

1987


ISSN/ISBN: 0385-0684
PMID: 3674894
Document Number: 292926
Thirteen patients with gynecologic cancer were treated with ifosfamide (2 g X 5), cisplatin (70 mg/m2) and adriamycin (20 mg/m2) combination chemotherapy. The response rate of 7 evaluable patients was 43%, with a median duration of survival of 14 months. Six patients with non-measurable disease are currently free from disease with a median duration of survival of 18 months. This combination caused reversible myelosuppression. No hemorrhagic cystitis was observed.

Document emailed within 1 workday
Secure & encrypted payments